S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
NASDAQ:CDMO

Avid Bioservices Stock Forecast, Price & News

$22.07
+0.04 (+0.18 %)
(As of 09/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$21.24
$22.32
50-Day Range
$19.05
$28.32
52-Week Range
$6.99
$28.36
Volume466,930 shs
Average Volume639,887 shs
Market Capitalization$1.35 billion
P/E Ratio275.91
Dividend YieldN/A
Beta2.19
30 days | 90 days | 365 days | Advanced Chart
Receive CDMO News and Ratings via Email

Sign-up to receive the latest news and ratings for Avid Bioservices and its competitors with MarketBeat's FREE daily newsletter.


Avid Bioservices logo

About Avid Bioservices

Avid Bioservices, Inc. engages in the commercial manufacturing. The firm focuses on the biopharmaceutical products derived from mammalian cell culture for culture for biotechnology and pharmaceutical companies. It specializes in clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory submissions and support. The company was founded on June 3, 1981 and is headquartered in Tustin, CA.

Headlines

Avid Bioservices (NASDAQ:CDMO) Shares Gap Up to $19.05
Avid Bioservices (NASDAQ:CDMO) Shares Gap Up to $19.05
September 17, 2021 |  americanbankingnews.com
Avid Bioservices (NASDAQ:CDMO) Shares Up 3.4%
Avid Bioservices (NASDAQ:CDMO) Shares Up 3.4%
September 16, 2021 |  americanbankingnews.com
Avid Bioservices (NASDAQ:CDMO) Shares Gap Down to $23.65
Avid Bioservices (NASDAQ:CDMO) Shares Gap Down to $23.65
September 9, 2021 |  americanbankingnews.com
Heres what Wall Street expects from Avid Bioservicess earnings report
Here's what Wall Street expects from Avid Bioservices's earnings report
September 8, 2021 |  markets.businessinsider.com
Avid Bioservices (NASDAQ:CDMO) Trading Down 3.6%
Avid Bioservices (NASDAQ:CDMO) Trading Down 3.6%
September 3, 2021 |  americanbankingnews.com
Avid Bioservices, Inc.(CDMO)
Avid Bioservices, Inc.(CDMO)
August 8, 2021 |  fool.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.48 out of 5 stars

Medical Sector

132nd out of 1,351 stocks

Pharmaceutical Preparations Industry

60th out of 664 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Avid Bioservices (NASDAQ:CDMO) Frequently Asked Questions

Is Avid Bioservices a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Avid Bioservices stock.
View analyst ratings for Avid Bioservices
or view top-rated stocks.

What stocks does MarketBeat like better than Avid Bioservices?

Wall Street analysts have given Avid Bioservices a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Avid Bioservices wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Avid Bioservices' next earnings date?

Avid Bioservices is scheduled to release its next quarterly earnings announcement on Wednesday, December 1st 2021.
View our earnings forecast for Avid Bioservices
.

How were Avid Bioservices' earnings last quarter?

Avid Bioservices, Inc. (NASDAQ:CDMO) issued its earnings results on Tuesday, September, 7th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.06. The biopharmaceutical company had revenue of $30.75 million for the quarter, compared to analyst estimates of $25 million. Avid Bioservices had a trailing twelve-month return on equity of 19.89% and a net margin of 12.63%. During the same period in the previous year, the business posted $0.06 earnings per share.
View Avid Bioservices' earnings history
.

How has Avid Bioservices' stock price been impacted by Coronavirus (COVID-19)?

Avid Bioservices' stock was trading at $4.51 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CDMO shares have increased by 389.4% and is now trading at $22.07.
View which stocks have been most impacted by COVID-19
.

When did Avid Bioservices' stock split? How did Avid Bioservices' stock split work?

Avid Bioservices's stock reverse split on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2017. An investor that had 100 shares of Avid Bioservices stock prior to the reverse split would have 14 shares after the split.

What guidance has Avid Bioservices issued on next quarter's earnings?

Avid Bioservices updated its FY 2022 earnings guidance on Thursday, September, 23rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $115 million-$117 million, compared to the consensus revenue estimate of $115.83 million.

What price target have analysts set for CDMO?

3 analysts have issued twelve-month target prices for Avid Bioservices' stock. Their forecasts range from $27.00 to $29.00. On average, they expect Avid Bioservices' share price to reach $28.00 in the next year. This suggests a possible upside of 26.9% from the stock's current price.
View analysts' price targets for Avid Bioservices
or view top-rated stocks among Wall Street analysts.

Who are Avid Bioservices' key executives?

Avid Bioservices' management team includes the following people:

What is Roger Lias' approval rating as Avid Bioservices' CEO?

2 employees have rated Avid Bioservices CEO Roger Lias on Glassdoor.com. Roger Lias has an approval rating of 49% among Avid Bioservices' employees. This puts Roger Lias in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Avid Bioservices own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avid Bioservices investors own include Array Technologies (ARRY), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Micron Technology (MU), QUALCOMM (QCOM), NVIDIA (NVDA), Novavax (NVAX) and Pfizer (PFE).

What is Avid Bioservices' stock symbol?

Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO."

Who are Avid Bioservices' major shareholders?

Avid Bioservices' stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (14.01%), BlackRock Inc. (7.09%), Vanguard Group Inc. (5.13%), State Street Corp (4.11%), AltraVue Capital LLC (3.58%) and Ranger Investment Management L.P. (3.22%). Company insiders that own Avid Bioservices stock include Daniel R Hart, Daniel Ryan Hart, Mark R Bamforth, Mark R Bamforth, Mark R Ziebell, Nicholas Stewart Green, Patrick D Walsh and Richard B Hancock.
View institutional ownership trends for Avid Bioservices
.

Which institutional investors are selling Avid Bioservices stock?

CDMO stock was sold by a variety of institutional investors in the last quarter, including AltraVue Capital LLC, Kornitzer Capital Management Inc. KS, JPMorgan Chase & Co., Schonfeld Strategic Advisors LLC, Cinctive Capital Management LP, AltraVue Capital LLC, Pier Capital LLC, and Kennedy Capital Management Inc.. Company insiders that have sold Avid Bioservices company stock in the last year include Daniel R Hart, Mark R Ziebell, and Nicholas Stewart Green.
View insider buying and selling activity for Avid Bioservices
or view top insider-selling stocks.

Which institutional investors are buying Avid Bioservices stock?

CDMO stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Bank of Montreal Can, Invesco Ltd., Jennison Associates LLC, FMR LLC, Goldman Sachs Group Inc., Dimensional Fund Advisors LP, and Morgan Stanley. Company insiders that have bought Avid Bioservices stock in the last two years include Daniel Ryan Hart, Mark R Bamforth, Patrick D Walsh, and Richard B Hancock.
View insider buying and selling activity for Avid Bioservices
or or view top insider-buying stocks.

How do I buy shares of Avid Bioservices?

Shares of CDMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avid Bioservices' stock price today?

One share of CDMO stock can currently be purchased for approximately $22.07.

How much money does Avid Bioservices make?

Avid Bioservices has a market capitalization of $1.35 billion and generates $95.87 million in revenue each year. The biopharmaceutical company earns $11.21 million in net income (profit) each year or $0.06 on an earnings per share basis.

How many employees does Avid Bioservices have?

Avid Bioservices employs 255 workers across the globe.

What is Avid Bioservices' official website?

The official website for Avid Bioservices is www.avidbio.com.

Where are Avid Bioservices' headquarters?

Avid Bioservices is headquartered at 2642 Michelle Drive Suite 200, TUSTIN CA, 92780.

How can I contact Avid Bioservices?

Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The biopharmaceutical company can be reached via phone at (714) 508-6100 or via email at [email protected].


This page was last updated on 9/25/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.